More than 15 abstracts showcase how the Veracyte Diagnostics Platform is advancing urologic cancer care with decisions guided by Decipher Prostate and Bladder tests SOUTH SAN FRANCISCO, ...
Source: Getty Images Investigators analyzed exfoliated cells in urine specimens to identify 50 candidate RNAs for prostate cancer detection. Serum PSA testing is not specific to prostate cancer, and ...
Australian scientists say it could also help reduce the risk of overdiagnosis by determining which cancers are low-risk and will never cause harm.
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today more than 15 abstracts featuring its urology portfolio will be presented at the 2026 ASCO Genitourinary Cancers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results